Top canonical pathways associated with acute phase of STEMI.

<p>Ingenuity Pathway Analysis of gene sets differentially expressed on the first day of myocardial infarction versus 6 months after MI or versus control group was performed. Functional categories are represented on the x-axis. The significance is expressed as the negative exponent on the p-value calculated for each function on the y-axis of the diagram, increasing with bar height.</p

Validation of microarray data using qRT-PCR.

***<p>p<0.001; **p<0.01; *p<0.05; ^NS – not significant.</p><p>All genes abbreviations are explained in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0050054#pone-0050054-t002" target="_blank">Table 2</a>.</p

Differentially expressed genes common to both analyses: admission versus control and discharge versus control.

<p>Differentially expressed genes common to both analyses: admission versus control and discharge versus control.</p

Differentially expressed genes common to both analyses: admission versus 6 months after MI and admission versus control.

<p>Differentially expressed genes common to both analyses: admission versus 6 months after MI and admission versus control.</p

Expression data from microarray experiments for chosen genes.

<p>The y-axis represents the log2 normalized intensity of the gene and the x-axis represents analyzed groups. The line inside the box and whiskers represents the median of the samples in a group. Points present relative expression levels in individual patients at admission (blue), at discharge (green), 6 month after MI (violet) and from control group (red). Numbers indicate the coded identity of a particular patient. SOCS3– suppressor of cytokine signaling 3; ST14– MT-SP1/matriptase; AQP 9– aquaporin 9; MYBL1– v-myb myeloblastosis viral oncogene homolog (avian)-like 1; STAB1– stabilin 1; ASGR2– asialoglycoprotein receptor 2.</p

Major characteristics of the study and control groups.

*<p>Mean ± Standard Deviation.</p>**<p>number (%);</p><p>NA – not applicable.</p